In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
--------
Question: SECTION 1. DEVELOPMENT OF BEST PRACTICES FOR THE USE OF PRESCRIPTION 
              OPIOIDS.

    (a) Definitions.--In this section--
            (1) the term ``Secretary'' means the Secretary of Health 
        and Human Services; and
            (2) the term ``task force'' means the Pain Management Best 
        Practices Inter-Agency Task Force convened under subsection 
        (b).
    (b) Inter-Agency Task Force.--Not later than December 14, 2018, the 
Secretary, in cooperation with the Secretary of Veterans Affairs, the 
Secretary of Defense, and the Administrator of the Drug Enforcement 
Administration, shall convene a Pain Management Best Practices Inter-
Agency Task Force to review, modify, and update, as appropriate, best 
practices for pain management (including chronic and acute pain) and 
prescribing pain medication.
    (c) Membership.--The task force shall be comprised of--
            (1) representatives of--
                    (A) the Department of Health and Human Services;
                    (B) the Department of Veterans Affairs;
                    (C) the Food and Drug Administration;
                    (D) the Department of Defense;
                    (E) the Drug Enforcement Administration;
                    (F) the Centers for Disease Control and Prevention;
                    (G) the Health Resources and Services 
                Administration;
                    (H) the Indian Health Service;
                    (I) the National Academy of Medicine;
                    (J) the National Institutes of Health;
                    (K) the Office of National Drug Control Policy;
                    (L) the Substance Abuse and Mental Health Services 
                Administration; and
                    (M) the Office of Women's Health;
            (2) State medical boards;
            (3) subject to subsection (e), physicians, dentists, and 
        nonphysician prescribers;
            (4) hospitals;
            (5) subject to subsection (e), pharmacists and pharmacies;
            (6) first responders;
            (7) experts in the fields of pain research and addiction 
        research;
            (8) experts in the fields of adolescent and young adult 
        addiction research;
            (9) representatives of--
                    (A) pain management professional organizations;
                    (B) the mental health treatment community;
                    (C) the addiction treatment and recovery community;
                    (D) pain advocacy groups;
                    (E) veteran service organizations; and
                    (F) groups with expertise on overdose reversal;
            (10) a person in recovery from addiction to medication for 
        chronic pain;
            (11) a person in recovery from addiction to medication for 
        chronic pain, whose addiction began in adolescence or young 
        adulthood;
            (12) a person with chronic pain;
            (13) an expert on active duty military, armed forces 
        personnel, and veteran health and prescription opioid 
        addiction;
            (14) an expert in the field of minority health; and
            (15) other stakeholders, as the Secretary determines 
        appropriate.
    (d) Condition on Participation on Task Force.--An individual 
representing a profession or entity described in paragraph (3) or (5) 
of subsection (c) may not serve as a member of the task force unless 
such individual--
            (1) is currently licensed in a State in which such 
        individual is practicing (as defined by such State) such 
        profession (or, in the case of an individual representing an 
        entity, a State in which the entity is engaged in business); 
        and
            (2) is currently practicing (as defined by such State) such 
        profession (or, in the case of an individual representing an 
        entity, the entity is in operation).
    (e) Duties.--The task force shall--
            (1) not later than 180 days after the date on which the 
        task force is convened under subsection (b), review, modify, 
        and update, as appropriate, best practices for pain management 
        (including chronic and acute pain) and prescribing pain 
        medication, taking into consideration--
                    (A) existing pain management research;
                    (B) research on trends in areas and communities in 
                which the prescription opioid abuse rate and fatality 
                rate exceed the national average prescription opioid 
                abuse rate and fatality rate;
                    (C) recommendations from relevant conferences and 
                existing relevant evidence-based guidelines;
                    (D) ongoing efforts at the State and local levels 
                and by medical professional organizations to develop 
                improved pain management strategies, including 
                consideration of differences within and between classes 
                of opioids, the availability of opioids with abuse 
                deterrent technology, and pharmacological, 
                nonpharmacological, medical device alternatives to 
                opioids to reduce opioid monotherapy in appropriate 
                cases and the coordination of information collected 
                from State prescription drug monitoring programs for 
                the purpose of preventing the diversion of pain 
                medication;
                    (E) ongoing efforts at the Federal, State, and 
                local levels to examine the potential benefits of 
                electronic prescribing of opioids, including any public 
                comments collected in the course of those efforts;
                    (F) the management of high-risk populations, other 
                than populations who suffer pain, who--
                            (i) may use or be prescribed 
                        benzodiazepines, alcohol, and diverted opioids; 
                        or
                            (ii) receive opioids in the course of 
                        medical care;
                    (G) the distinct needs of adolescents and young 
                adults with respect to pain management, pain 
                medication, substance use disorder, and medication-
                assisted treatment;
                    (H) the 2016 Guideline for Prescribing Opioids for 
                Chronic Pain issued by the Centers for Disease Control 
                and Prevention;
                    (I) the practice of co-prescribing naloxone for 
                both pain patients receiving chronic opioid therapy and 
                patients being treated for opioid use disorders;
                    (J) research that has been, or is being, conducted 
                or supported by the Federal Government on prevention 
                of, treatment for, and recovery from substance use by 
                and substance use disorders among adolescents and young 
                adults relative to any unique circumstances (including 
                social and biological circumstances) of adolescents and 
                young adults that may make adolescent-specific and 
                young adult-specific treatment protocols necessary, 
                including any effects that substance use and substance 
                use disorders may have on brain development and the 
                implications for treatment and recovery;
                    (K) Federal non-research programs and activities 
                that address prevention of, treatment for, and recovery 
                from substance use by and substance use disorders among 
                adolescents and young adults, including an assessment 
                of the effectiveness of such programs and activities 
                in--
                            (i) preventing substance use by and 
                        substance use disorders among adolescents and 
                        young adults;
                            (ii) treating such adolescents and young 
                        adults in a way that accounts for any unique 
                        circumstances faced by adolescents and young 
                        adults; and
                            (iii) supporting long-term recovery among 
                        adolescents and young adults; and
                    (L) gaps that have been identified by Federal 
                officials and experts in Federal efforts relating to 
                prevention of, treatment for, and recovery from 
                substance use by and substance use disorders among 
                adolescents and young adults, including gaps in 
                research, data collection, and measures to evaluate the 
                effectiveness of Federal efforts, and the reasons for 
                such gaps;
            (2) solicit and take into consideration public comment on 
        the practices developed under paragraph (1), amending such best 
        practices if appropriate;
            (3) develop a strategy for disseminating information about 
        the best practices developed under paragraphs (1) and (2) to 
        prescribers, pharmacists, State medical boards, educational 
        institutions that educate prescribers and pharmacists, and 
        other parties, as the Secretary determines appropriate;
            (4) review, modify, and update best practices for pain 
        management and prescribing pain medication, specifically as it 
        pertains to physician education and consumer education; and
            (5) examine and identify--
                    (A) the extent of the need for the development of 
                new pharmacological, nonpharmacological, and medical 
                device alternatives to opioids;
                    (B) the current status of research efforts to 
                develop such alternatives; and
                    (C) the pharmacological, nonpharmacological, and 
                medical device alternatives to opioids that are 
                currently available that could be better utilized.
    (f) Consideration of Study Results.--In reviewing, modifying, and 
updating, best practices for pain management and prescribing pain 
medication, the task force shall take into consideration existing 
private sector, State, and local government efforts related to pain 
management and prescribing pain medication.
    (g) Limitation.--The task force shall not have rulemaking 
authority.
    (h) Report.--Not later than 270 days after the date on which the 
task force is convened under subsection (b), the task force shall 
submit to Congress a report that includes--
            (1) the strategy for disseminating best practices for pain 
        management (including chronic and acute pain) and prescribing 
        pain medication, as developed under subsection (e);
            (2) the results of a feasibility study on linking the best 
        practices described in paragraph (1) to receiving and renewing 
        registrations under section 303(f) of the Controlled Substances 
        Act (21 U.S.C. 823(f));
            (3) recommendations for effectively applying the best 
        practices described in paragraph (1) to improve prescribing 
        practices at medical facilities, including medical facilities 
        of the Veterans Health Administration and Indian Health 
        Service;
            (4) the modified and updated best practices described in 
        subsection (e)(4); and
            (5) the results of the examination and identification 
        conducted pursuant to subsection (e)(4), and recommendations 
        regarding--
                    (A) the development of new pharmacological, 
                nonpharmacological, and medical device alternatives to 
                opioids; and
                    (B) the improved utilization of pharmacological, 
                nonpharmacological, and medical device alternatives to 
                opioids that are currently available.

            Passed the House of Representatives May 11, 2016.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.

Answer: (Sec. 1) This bill requires the Department of Health and Human Services to convene a Pain Management Best Practices Inter-Agency Task Force to: (1) review, modify, and update best practices for pain management and prescribing pain medication; and (2) examine and identify the need for, development of, and availability of medical alternatives to opioids (drugs with effects similar to opium, such as certain pain medications). The task force must submit a report that includes: (1) the modified and updated best practices; (2) a strategy for disseminating the best practices; (3) the feasibility of linking the best practices to Drug Enforcement Administration registration of manufacturers, distributors, and dispensers of controlled substances; (4) recommendations for effectively applying the best practices at medical facilities; and (5) recommendations regarding medical alternatives to opioids.


Question: SECTION 1. AMENDMENTS TO UNITED STATES INSULAR POSSESSION PROGRAM.

    (a) Production Certificates.--The additional U.S. Note 5(h) to 
chapter 91 of the Harmonized Tariff Schedule of the United States is 
amended--
            (1) by amending subparagraphs (i) and (ii) to read as 
        follows:
``(i) In the case of each calendar quarter beginning after January 1, 
        2002, and before January 1, 2016, the Secretaries jointly, 
        shall:
        ``(A) verify for the preceding calendar quarter both the wages 
                paid by each producer to permanent residents of the 
                insular possessions (including the value of any fringe 
                benefits) and the total quantity and value of watches 
                produced in the insular possessions and imported into 
                the customs territory of the United States; and
        ``(B) issue to each producer (not later than 30 days after the 
                end of the calendar quarter) a certificate for the 
                applicable amount.
``(ii) For purposes of subparagraph (i), except as provided in 
        subparagraphs (iii) and (iv), the term `applicable amount' 
        means an amount equal to the sum of:
        ``(A) 90 percent of the producer's creditable wages (including 
                the value of any fringe benefits) on watch assembly 
                during the preceding calendar quarter (but only the 
                first 300,000 units per calendar year); plus
        ``(B) the applicable graduated declining percentage (determined 
                each year by the Secretaries) of the producer's 
                creditable wages (including the value of any fringe 
                benefits) on the assembly during the preceding calendar 
                quarter for units in excess of 300,000 that calendar 
                year, but not in excess of 750,000 that calendar year; 
                plus
        ``(C) the difference between the duties that would have been 
                due on the producer's watches (excluding digital 
                watches) imported into the customs territory of the 
                United States during the preceding quarter if they had 
                been imported from a country eligible for normal trade 
                relations subject to duty at the rates set forth in 
                column 1 under this chapter that were in effect on 
                January 1, 2001, and the duties that would have been 
                due on those watches if they had been imported from the 
                same country under the tariffs in effect for the 
                preceding calendar quarter.''; and
            (2) by amending subparagraph (v) to read as follows:
``(v)(A) Any certificate issued under subparagraph (i) shall entitle 
        the certificate holder to secure the refund of duties equal to 
        the face value of the certificate on watches, watch movements 
        and, with the exception of discrete cases, parts therefor 
        imported into the customs territory of the United States by the 
        certificate holder. Such refunds shall be made under 
        regulations issued by the Treasury Department. Not more than 5 
        percent of such refunds may be retained as a reimbursement to 
        the Customs Service for the administrative costs of making the 
        refunds. If the Secretary of the Treasury determines that there 
        is an insufficient level of duties from watch and watch-related 
        tariffs, the Secretary may authorize refunds of duties 
        collected on jewelry under chapter 71 or any other duties that 
        the Secretary determines are appropriate.
``(B) At the election of the certificate holder and upon making the 
        certification described in this clause, the Secretary of the 
        Treasury shall pay to the holder the face value of the 
        certificate, less the value of (1) any duty refund claimed by 
        the holder under the certificate, plus (2) a discount of not 
        more than 2 percent of the face value of the certificate, as 
        determined by the Secretary of the Treasury. A certificate 
        holder shall not be eligible for direct payment under this 
        clause unless the certificate holder certifies to the 
        Secretaries that the funds received will be reinvested or 
        utilized to support and continue employment in the Virgin 
        Islands.
``(C) The Secretary of the Treasury is authorized to make the payments 
        provided for in clause (B) from duties collected on watches, 
        watch movements and, with the exception of discrete cases, 
        parts therefor. If such duties are insufficient, the Secretary 
        of the Treasury is authorized to make those payments from 
        duties collected on jewelry under chapter 71 or any other 
        duties that the Secretary determines are appropriate.''.
    (b) Jewelry.--Additional U.S. Note to chapter 71 of the Harmonized 
Tariff Schedule of the United States is amended--
            (1) by redesignating paragraphs (b), (c), (d), and (e) as 
        paragraphs (c), (d), (e), and (f), respectively;
            (2) by inserting after paragraph (a) the following new 
        paragraph:
``(b) The 750,000 unit limitation in additional U.S. Note 5(h)(ii)(B) 
        to chapter 91 shall not apply to articles of jewelry subject to 
        this note.''; and
            (3) by striking paragraph (f), as so redesignated, and 
        inserting the following:
``(f) Notwithstanding any other provision of law, prior to February 9, 
        2004, any article of jewelry provided for in heading 7113 that 
        is assembled in the Virgin Islands, Guam, or American Samoa 
        shall be treated as a product of the Virgin Islands, Guam, or 
        American Samoa for purposes of this note and General Note 
        3(a)(iv) of this Schedule.''.

SEC. 2. EFFECTIVE DATE.

    The amendments made by this Act shall take effect on April 1, 2002, 
with respect to goods imported into the customs territory of the United 
States on or after January 1, 2002.

Answer: Amends the Harmonized Tariff Schedule of the United States to revise clock and watch provisions to require the Secretary of Commerce and the Secretary of the Interior, jointly, for each calendar quarter beginning after January 1, 2002, and before January 1, 2016, to: (1) verify for the preceding calendar quarter both the wages paid by each producer to permanent residents of the insular possessions (including the value of any fringe benefits) and the total quantity and value of watches produced there and imported into the U.S. customs territory; and (2) issue to each producer a certificate for the applicable amount.Directs the Secretary of the Treasury, at the election of the certificate holder, to pay to the holder the face value of the certificate, less the value of any duty refund claimed by the holder under the certificate, plus a discount of not more than two percent of the face value of the certificate as determined by the Secretary of the Treasury.


Question: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Directed Energy Weapon Systems 
Acquisition Act of 2016''.

SEC. 2. FINDINGS.

    Congress makes the following findings:
            (1) The Committee on Armed Services of the Senate noted in 
        the report accompanying S. 1356 (S. Rept. 114-49; 114th 
        Congress) that since 1960, the Department of Defense has 
        invested more than $6,000,000,000 in directed energy science 
        and technology initiatives, and that the Committee is concerned 
        that, despite this significant investment, the Department's 
        directed energy initiatives are not resourced at levels 
        necessary to transition them to full-scale acquisition 
        programs.
            (2) The Defense Science Board Task Force on Directed Energy 
        Weapon Systems and Technology Applications (the ``Task Force'') 
        found that ``directed energy offers promise as a 
        transformational `game changer' in military operations, able to 
        augment and improve operational capabilities in many areas''.
            (3) Despite this potential, years of investment have not 
        resulted in any operational systems with high energy laser 
        capability.
            (4) The Task Force believes that the range of potential 
        application is sufficient to warrant significantly increased 
        attention to the scope and direction of efforts to assess, 
        develop, and field appropriate laser, microwave, and millimeter 
        wave weapons.

SEC. 3. INCLUSION OF DIRECTED ENERGY WEAPON SYSTEM PROGRAMS IN THE 
              RAPID ACQUISITION AUTHORITY PROGRAM.

    (a) In General.--Section 806(c)(1) of the Bob Stump National 
Defense Authorization Act for Fiscal Year 2003 (Public Law 107-314; 10 
U.S.C. 2302 note) is amended by adding at the end the following new 
subparagraph:
            ``(D)(i) In the case of any supplies and associated support 
        services that, as determined in writing by the Secretary of 
        Defense without delegation, are urgently needed to eliminate a 
        deficiency in directed energy weapon systems, the Secretary may 
        use the procedures developed under this section in order to 
        accomplish the rapid acquisition and deployment of needed 
        offensive or defensive directed energy weapon systems 
        capabilities, supplies, and associated support services.
            ``(ii) For the purposes of directed energy weapon systems 
        acquisition, the Secretary of Defense shall consider use of the 
        following procedures:
                    ``(I) The rapid acquisition authority provided 
                under this section.
                    ``(II) Use of other transactions authority provided 
                under section 2371 of title 10, United States Code.
                    ``(III) The acquisition of commercial items using 
                simplified acquisition procedures.
                    ``(IV) The authority for procurement for 
                experimental purposes provided under section 2373 of 
                title 10, United States Code.
            ``(iii) In this subparagraph, the term `directed energy 
        weapon system' means military action involving the use of 
        directed energy to incapacitate, damage, or destroy enemy 
        equipment, facilities, or personnel.''.
    (b) Conforming Amendments.--Section 2373 of title 10, United States 
Code, is amended--
            (1) in subsection (a), by striking ``and aeronautical 
        supplies'' and inserting ``, aeronautical supplies, and 
        directed energy weapon systems''; and
            (2) by adding at the end of the following new subsection:
    ``(c) Directed Energy Weapon System Defined.--In this section, the 
term `directed energy weapon system' means military action involving 
the use of directed energy to incapacitate, damage, or destroy enemy 
equipment, facilities, or personnel.''.

SEC. 4. JOINT DIRECTED ENERGY PROGRAM OFFICE.

    (a) Redesignation.--The High Energy Laser Joint Technology Office 
of the Department of Defense is hereby redesignated as the ``Joint 
Directed Energy Program Office'' (in this section referred to as the 
``Office'').
    (b) Strategic Plan for Development and Transition of Directed 
Energy Weapons Capabilities Toward Fielding.--In addition to the 
functions and duties of the Office in effect on the day before the date 
of the enactment of this Act, the Office shall develop a strategic plan 
for development and transition of directed energy weapons capabilities 
toward fielding for the Department, in which the Office may define 
requirements for directed energy capabilities that address the highest 
priority warfighting capability gaps of the Department.
    (c) Acceleration of Development and Transition of Directed Energy 
Weapons Capabilities Toward Fielding.--
            (1) In general.--To the degree practicable, the Office 
        shall use the policies of the Department that are revised 
        pursuant to this Act and new acquisition and management 
        practices established pursuant to this Act to accelerate the 
        development and transition of directed energy capabilities 
        toward fielding.
            (2) Engagement.--The Secretary shall ensure that use of 
        policies and practices described in paragraph (1) include 
        engagement with defense and private industries, research 
        universities, and unaffiliated, nonprofit research 
        institutions.

Answer:
Directed Energy Weapon Systems Acquisition Act of 2016 This bill amends the Bob Stump National Defense Authorization Act for Fiscal Year 2003 to state that, if supplies or support services are urgently needed to eliminate a deficiency in directed energy weapon systems, the Department of Defense (DOD) may use specified rapid acquisition procedures to acquire and deploy needed offensive or defensive directed energy weapon systems capabilities, supplies, and associated support services.  &quot;Directed energy weapon system&quot; means military action using highly focused sound, electromagnetic, or particle-beam energy to incapacitate, damage, or destroy enemy equipment, facilities, or personnel. The bill redesignates DOD's High Energy Laser Joint Technology Office as the Joint Directed Energy Program Office. The Office shall: (1) develop a strategic plan for development and transition of directed energy weapons capabilities, and (2) use new and revised DOD policies to accelerate the development and transition of directed energy capabilities toward fielding.